These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 23219328

  • 1. Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists.
    Thomas AS, Mehta AB, Hughes DA.
    Blood Cells Mol Dis; 2013 Mar; 50(3):212-7. PubMed ID: 23219328
    [Abstract] [Full Text] [Related]

  • 2. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention.
    Mistry PK, Sadan S, Yang R, Yee J, Yang M.
    Am J Hematol; 2007 Aug; 82(8):697-701. PubMed ID: 17492645
    [Abstract] [Full Text] [Related]

  • 3. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 4. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
    Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE.
    Blood Cells Mol Dis; 2010 Mar 15; 44(3):181-7. PubMed ID: 20074983
    [Abstract] [Full Text] [Related]

  • 5. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S, Roberts A, Patterson MA, Amato D.
    Blood Cells Mol Dis; 2009 Mar 15; 43(3):289-93. PubMed ID: 19793665
    [Abstract] [Full Text] [Related]

  • 6. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 15; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 7. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
    Kaplan P, Andersson HC, Kacena KA, Yee JD.
    Arch Pediatr Adolesc Med; 2006 Jun 15; 160(6):603-8. PubMed ID: 16754822
    [Abstract] [Full Text] [Related]

  • 8. Clinical and enzyme studies in Gaucher disease.
    Kaur M, Kabra M, Kher A, Naik G, Bharucha BA, Verma IC.
    Indian Pediatr; 1996 Sep 15; 33(9):735-8. PubMed ID: 9057400
    [Abstract] [Full Text] [Related]

  • 9. Cross-sectional web-based survey among haematologists and gastroenterologists in Japan to identify the key factors for early diagnosis of Gaucher disease.
    Yoshimitsu M, Ono M, Inoue Y, Sagara R, Baba T, Fernandez J.
    Intern Med J; 2023 Jun 15; 53(6):930-938. PubMed ID: 35499124
    [Abstract] [Full Text] [Related]

  • 10. Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm.
    Di Rocco M, Andria G, Deodato F, Giona F, Micalizzi C, Pession A.
    Pediatr Blood Cancer; 2014 Nov 15; 61(11):1905-9. PubMed ID: 25131373
    [Abstract] [Full Text] [Related]

  • 11. Mild thrombocytopenia as presenting symptom of type 1 Gauchers's disease.
    Müzes G, Pitlik E, Somogyi A, Tulassay Z.
    Z Gastroenterol; 2001 Jun 15; 39(6):471-4. PubMed ID: 11475003
    [Abstract] [Full Text] [Related]

  • 12. Diagnosis and Management of Gaucher Disease in India - Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics.
    Puri RD, Kapoor S, Kishnani PS, Dalal A, Gupta N, Muranjan M, Phadke SR, Sachdeva A, Verma IC, Mistry PK, Gaucher Disease Task Force.
    Indian Pediatr; 2018 Feb 15; 55(2):143-153. PubMed ID: 29503270
    [Abstract] [Full Text] [Related]

  • 13. [Phenotype and mutational spectrum in Tunisian pediatric gaucher disease].
    Ben Turkia H, Riahi I, Azzouz H, Ladab S, Cherif W, Ben Chehida A, Abdelmoula MS, Caillaud C, Chemli J, Abdelhak S, Tebib N, Ben Dridi MF.
    Tunis Med; 2010 Mar 15; 88(3):158-62. PubMed ID: 20415187
    [Abstract] [Full Text] [Related]

  • 14. [An adult form of type-I. Gaucher's disease].
    Múzes G, Pitlik E, Gohér A, Somogyi A, Tulassay Z.
    Orv Hetil; 2000 Mar 26; 141(13):669-73. PubMed ID: 10774238
    [Abstract] [Full Text] [Related]

  • 15. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 26; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 16. Gaucher disease--Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment.
    Erikson A.
    Acta Paediatr Scand Suppl; 1986 Feb 26; 326():1-42. PubMed ID: 3296644
    [Abstract] [Full Text] [Related]

  • 17. [Gaucher disease type I diagnosed at 63 years old presenting with thrombocytopenia].
    Kawahara S, Kato A, Oshimi K, Ida H.
    Rinsho Ketsueki; 2008 May 26; 49(5):335-9. PubMed ID: 18572811
    [Abstract] [Full Text] [Related]

  • 18. Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment.
    Mekinian A, Stirnemann J, Belmatoug N, Heraoui D, Fantin B, Fain O, Charpentier A, Rose C.
    Blood Cells Mol Dis; 2012 Jun 15; 49(1):53-7. PubMed ID: 22560483
    [Abstract] [Full Text] [Related]

  • 19. Giant lymphadenopathy infiltrated by gaucher cells mimicking lymphoma.
    Yağci B, Salor O, Yalçin B, Gürakan F, Güçer S, Büyükpamukçu M.
    Pediatr Blood Cancer; 2009 Jul 15; 52(7):870-1. PubMed ID: 19213078
    [Abstract] [Full Text] [Related]

  • 20. Gaucher disease. Unusual presentation and mini-review.
    Rizk TM, Ariganjoye RO, Alsaeed GI.
    Neurosciences (Riyadh); 2015 Jul 15; 20(3):271-6. PubMed ID: 26166597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.